Parathyroid

Endocrinology·MeSH: Hypoparathyroidism

Prevalence

0.5 / 100K

31 drugs in development·11 companies·1 clinical trial

Drug Pipeline by Phase

Approved(5)

Drug	Company
cinacalcet	DR REDDYS LABORATORIES LTD (RDY)
doxercalciferol	Amneal Pharmaceuticals, Inc. (AMRX)
rayaldee	OPKO HEALTH, INC. (OPK)
rayaldee	REPLIGEN CORP (RGEN)
yorvipath	Ascendis Pharma A/S (ASND)

Phase 2(8)

Phase 1(16)

Drug	Company
ebp05	Entera Bio Ltd. (ENTX)
EBP05	ENANTA PHARMACEUTICALS INC (ENTA)
ebp11	Entera Bio Ltd. (ENTX)
EBP11	ENANTA PHARMACEUTICALS INC (ENTA)
ebp11-f1	Entera Bio Ltd. (ENTX)
EBP11-F1	ENANTA PHARMACEUTICALS INC (ENTA)
ebp11-f2	Entera Bio Ltd. (ENTX)
EBP11-F2	ENANTA PHARMACEUTICALS INC (ENTA)
ebp11-f4	Entera Bio Ltd. (ENTX)
EBP11-F4	ENANTA PHARMACEUTICALS INC (ENTA)
ebp11-f5	Entera Bio Ltd. (ENTX)
EBP11-F5	ENANTA PHARMACEUTICALS INC (ENTA)
ebp22	Entera Bio Ltd. (ENTX)
EBP22	ENANTA PHARMACEUTICALS INC (ENTA)
forteo	Entera Bio Ltd. (ENTX)
Forteo 0.02 mg	ENANTA PHARMACEUTICALS INC (ENTA)

Preclinical(2)

Drug	Company
Parathyroid Hormone Antagonist Program	Crinetics Pharmaceuticals, Inc. (CRNX)
pth1r agonist	Septerna, Inc. (SEPN)

BioSniper tracks 31 drugs in development for Parathyroid across 11 companies.

There are 1 clinical trial targeting Parathyroid tracked by BioSniper.

The estimated prevalence of Parathyroid is approximately 0.5 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.